期刊
CANCER RESEARCH
卷 74, 期 7, 页码 1958-1968出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-13-2084
关键词
-
类别
资金
- FEDER funds (EU) from the Instituto de Salud Carlos III [CP03/0111, PI12/02031, PI 08/1265, PI 11/01022, RETIC RD 06/020, RD09/0076/00165]
- Junta de Andalucia [CTS-143, CTS-695, CTS-3952, CVI-4740]
- European Community [LSHC-CT-2004-503306, OJ 2004/c158, 18234]
- Miguel Servet [CP03/0111]
- FPS and ISCIII [I3]
- ISCIII [CM12/00033]
- FPU-MEC [1631]
Tumor dormancy is a clinical phenomenon related to immune equilibrium during cancer immunoediting. The mechanisms involved in dormant metastases are poorly understood due to the lack of preclinical models. Here, we present a nontransgenic mouse model in which spontaneous metastases remain in permanent immunomediated dormancy with no additional antitumor treatment. After the injection of a GR9-B11 mouse fibrosarcoma clone into syngeneic BALB/c mice, all animals remained free of spontaneous metastases at the experimental endpoints (3-8 months) but also as long as 24 months after tumor cell injection. Strikingly, when tumor-bearing mice were immunodepleted of T lymphocytes or asialo GM1-positive cells, the restraint on dormant disseminated metastatic cells was relieved and lung metastases progressed. Immunostimulation was documented at both local and systemic levels, with results supporting the evidence that the immune system was able to restrain spontaneous metastases in permanent dormancy. Notably, the GR9-B11 tumor clone did not express MHC class I molecules on the cell surface, yet all metastases in immunodepleted mice were MHC class I-positive. This model system may be valuable for more in-depth analyses of metastatic dormancy, offering new opportunities for immunotherapeutic management of metastatic disease. (C)2014 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据